Third Rock-Launched GBT Raises $40.7M in Series A
Global Blood Therapeutics Inc. (GBT) came charging out of the gate Thursday with a $40.7 million Series A, becoming the first company "organically constructed, formed and launched" from the West Coast office of Third Rock Ventures LLC, according to Mark A. Goldsmith, the company's CEO and a Third Rock venture partner.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST